AstraZeneca (AZN) Stock Forecast & Price Target

£124.96 -114.00 (-0.90%)

As of 05:22 AM Eastern

Compare

AstraZeneca - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 6 Analyst Ratings

Sell
1

Hold
0

Buy
5

Based on 6 Wall Street analysts who have issued ratings for AstraZeneca in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 6 analysts, 1 has given a sell rating, and 5 have given a buy rating for AZN.

Consensus Price Target

£153.33

According to the 6 analysts' twelve-month price targets for AstraZeneca, the average price target is £153.33. The highest price target for AZN is £180, while the lowest price target for AZN is £115. The average price target represents a forecasted upside of 22.71% from the current price of £124.96.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for AZN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for AstraZeneca and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AZN Analyst Ratings Over Time

Type	Current Forecast 7/14/25 to 7/14/26	1 Month Ago 6/14/25 to 6/14/26	3 Months Ago 4/15/25 to 4/15/26	1 Year Ago 7/14/24 to 7/14/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	5 Buy rating(s)	5 Buy rating(s)	3 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	£153.33	£153.33	£152.50	GBX 8,380
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

AZN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

AZN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

AstraZeneca Stock vs. The Competition

Type	AstraZeneca	Medical Companies
Consensus Rating Score	2.67	2.30
Consensus Rating	Moderate Buy	Hold
News Sentiment Rating	Neutral News See Recent AZN News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Action	Rating	Price Target	Report Date Upside/Downside
7/10/2026	Citigroup 4 of 5 stars	Downgrade	Buy
6/26/2026	Deutsche Bank Aktiengesellschaft 2 of 5 stars	Reiterated Rating	Sell	£115 ➝ £115	-19.52%
6/26/2026	Jefferies Financial Group 3 of 5 stars	Reiterated Rating	Buy	£180 ➝ £180	+25.96%
1/27/2026	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Target	Buy	£145 ➝ £160	+17.94%
1/16/2026	Shore Capital Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
1/15/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 05:48 AM ET.

Should I Buy AstraZeneca Stock? AZN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, July 13, 2026. Please send any questions or comments about these AstraZeneca pros and cons to contact@marketbeat.com.

AstraZeneca
Bull Case

Here are some ways that investors could benefit from investing in AstraZeneca PLC:

The current stock price is around £134.96, which reflects a strong market position and investor confidence in the company's future growth.
AstraZeneca PLC has a robust pipeline of innovative medicines, particularly in Oncology and Respiratory & Immunology, which are key areas of growth in the biopharmaceutical industry.
The company has demonstrated strong financial performance with a market capitalization of approximately £210.69 billion, indicating its significant presence in the market.
With a low beta of 0.17, AstraZeneca PLC's stock is less volatile compared to the broader market, making it a potentially safer investment during uncertain economic times.
The PEG ratio of 0.86 suggests that the stock may be undervalued relative to its earnings growth potential, making it an attractive option for growth-oriented investors.

AstraZeneca
Bear Case

Investors should be bearish about investing in AstraZeneca PLC for these reasons:

The price-to-earnings ratio of 22.58 indicates that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
Insider selling activity, such as the recent sale of shares by Nazneen Rahman, may raise concerns about the company's future prospects and insider confidence.
Despite its strong market position, AstraZeneca PLC faces intense competition in the biopharmaceutical sector, which could impact its market share and profitability.
The company operates in a highly regulated industry, and any changes in regulations or approval processes could adversely affect its operations and product launches.
Market fluctuations and economic uncertainties can impact the overall performance of the pharmaceutical sector, potentially affecting AstraZeneca PLC's stock performance.

AZN Forecast - Frequently Asked Questions

According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for AstraZeneca is £153.33, with a high forecast of £180 and a low forecast of £115.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There is currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AZN shares.

According to analysts, AstraZeneca's stock has a predicted upside of 22.71% based on their 12-month stock forecasts.

Over the previous 90 days, AstraZeneca's stock had 1 downgrade by analysts.

AstraZeneca has been rated by research analysts at Citigroup, Deutsche Bank Aktiengesellschaft, and Jefferies Financial Group in the past 90 days.

Analysts like AstraZeneca more than other "medical" companies. The consensus rating for AstraZeneca is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how AZN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With AstraZeneca Recommendations

This page (LON:AZN) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AstraZeneca (AZN) Stock Forecast & Price Target

AstraZeneca - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

AZN Analyst Ratings Over Time

AZN Analyst Recommendations By Month

AZN Price Targets by Month

AstraZeneca Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy AstraZeneca Stock? AZN Pros and Cons Explained

AstraZeneca
Bull Case

AstraZeneca
Bear Case

AZN Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With AstraZeneca Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AstraZeneca (AZN) Stock Forecast & Price Target

AstraZeneca - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

AZN Analyst Ratings Over Time

AZN Analyst Recommendations By Month

AZN Price Targets by Month

AstraZeneca Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy AstraZeneca Stock? AZN Pros and Cons Explained

AstraZeneca Bull Case

AstraZeneca Bear Case

AZN Forecast - Frequently Asked Questions

What is AstraZeneca's forecast for 2026?

Should I buy or sell AstraZeneca stock right now?

Does AstraZeneca's stock price have much upside?

Has AstraZeneca been downgraded by Wall Street analysts recently?

What analysts cover AstraZeneca?

Do Wall Street analysts like AstraZeneca more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With AstraZeneca Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

AstraZeneca
Bull Case

AstraZeneca
Bear Case